Skip to main content

Mutanome Engineered RNA Immuno-Therapy

Objectif

The Mutanome Engineered RNA Immuno-Therapy (MERIT) project aims to clinically translate and industrially validate a pioneering RNA-based immunotherapy approach to target the individual tumour antigen signature. MERIT focuses on previous inventions, fits into the overall business and innovation needs of the partners, and addresses triple-negative breast cancer patients with high medical need. The MERIT concept, including patents and potential products, was developed using EU FP6 funding. The innovative therapeutics will pave the way for generation of scientific knowledge and technologies and will stimulate the development of new products, tools, patents, and innovative marketable applications.
The concept behind MERIT is to implement a highly innovative Next-Generation-Immunotherapy drug platform enabling Next–Generation-Sequencing-guided stratified medicine and clinical-grade individualized RNA vaccines. Every patient’s tumour expresses many shared tumour-specific antigens and bears a highly individual molecular “signature” comprising 10’s to 100’s of non-synonymous mutations, many of which are immunogenic. We will use clinical-grade RNA to produce a) a warehouse of therapeutic vaccines targeting shared antigens and b) custom therapeutic vaccines targeting patient-specific mutations. Upon success, partner BioNTech will move the therapeutics to advanced clinical trials and commercial applications for the benefit of triple negative breast cancer patients and other solid tumours.

Appel à propositions

FP7-HEALTH-2013-INNOVATION-2
Voir d’autres projets de cet appel

Coordinateur

BIONTECH AG
Adresse
Holderlinstrasse 8
55131 Mainz
Allemagne

Voir sur la carte

Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contact administratif
Ugur Sahin (Prof.)
Contribution de l’UE
€ 4 456 750

Participants (4)

INSTITUT GUSTAVE ROUSSY
France
Contribution de l’UE
€ 453 750
Adresse
Rue Camille Desmoulins 39
94805 Villejuif

Voir sur la carte

Type d’activité
Research Organisations
Contact administratif
Arnauld Forest (Mr.)
VRIJE UNIVERSITEIT BRUSSEL
Belgique
Contribution de l’UE
€ 401 250
Adresse
Pleinlaan 2
1050 Brussel

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Nik Claesen (Mr.)
University of Zurich
Suisse
Contribution de l’UE
€ 315 000
Adresse
Ramistrasse 71
8006 Zurich

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Steve Pascolo (Dr.)
UPPSALA UNIVERSITET
Suède
Contribution de l’UE
€ 337 500
Adresse
Von Kraemers Alle 4
751 05 Uppsala

Voir sur la carte

Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Pirkko Boox (Mrs.)